Nonetheless, a comprehensive analysis is imperative to determine the potential cost-effectiveness of employing and integrating 68Ga-PSMA-11 PET/CT for the primary diagnosis of patients with suspected prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.